Lipid Metabolic Disorders: a Pivotal Driver in Type 2 Diabetes Mellitus Pathogenesis

Area of Science:

• Metabolic disorders
• Endocrinology
• Diabetes research

Background:

• Dyslipidemia, characterized by elevated free fatty acids (FFAs), triglycerides (TGs), and LDL-C with reduced HDL-C, is common in insulin resistant (IR) individuals.
• These lipid abnormalities are increasingly recognized not as mere comorbidities but as early, critical drivers of type 2 diabetes mellitus (T2DM) pathogenesis.

Purpose of the Study:

• To synthesize current evidence on the causal and mechanistic links between lipid metabolism disorders and T2DM.
• To review novel therapeutic strategies targeting key molecular and physiological nodes in the T2DM pathophysiological cascade.
• To establish an integrated framework for precision management of T2DM.

Main Methods:

• Literature review and evidence synthesis.
• Analysis of recent findings on lipid metabolism and T2DM.
• Evaluation of emerging therapeutic interventions.

Main Results:

• Lipid metabolism disorders initiate a pathological cascade involving ectopic lipid accumulation, systemic insulin resistance (IR) in liver and muscle, and direct lipotoxic stress on pancreatic beta-cells.
• Disruption of inter-organ axes, including the gut-adipose-liver and brain-periphery axes, exacerbates metabolic deterioration.
• Adipose dysfunction is identified as a key initiating event in this cascade.

Conclusions:

• Lipid metabolism disorders are central drivers of T2DM progression, not just consequences.
• Targeting lipotoxicity and inter-organ communication pathways offers promising avenues for precision T2DM therapy.
• Restoring metabolic health through interventions along the gut-brain-liver-fat axis is a key therapeutic goal.